Search More. Pay Less.
Information is the Raw Material for the AI Age
Web-scale search that's 100× cheaper, 10× faster, accurate & fully independent.
$0.05
Per 1K queries
50ms
As fast as
40B+
Web pages
Files
Conversations
Agents
Web
Reports
Documentation
Files
Conversations
Agents
Web
Reports
Documentation
Search Costs More Than Intelligence
LLMs need search. Training cutoffs mean LLM's know nothing about the last 6 months. Search gives LLMs access to current, accurate information.
Search APIs cost up to $14 per 1K queries - making it the dominant cost in any AI stack. Intelligent LLMs cost as little as $0.15 per 1K queries. These workhorse models are used the most and need search the most, but so far, it has been too expensive to pair with them.
Grok-4-1-fast + Competitor search
Model $0.15
Search $14.00
Total / 1K queries $14.15
Grok-4-1-fast + Ceramic
Model $0.15
Search $0.05
Total / 1K queries $0.20
* Model cost based on output pricing at ~300 tokens per response (0.3M output tokens ≈ 1K queries)
Ceramic Web API
Ceramic gives AI the ability to search more and unlock new use cases.
Query:
“What are the latest developments with GLP-1 weight loss drugs?”
No Search
LLM with no web access
0 Searches
GLP-1 receptor agonists like Ozempic (semaglutide) and Mounjaro (tirzepatide) have become popular weight loss treatments. Wegovy received FDA approval for chronic weight management in 2021.
Outdated — training data cutoff
Competitor Search API
$14.00 per 1,000 queries *
- • GLP-1 weight loss drugs 2025
- • ozempic wegovy latest news
- • new obesity drugs FDA
3 Searches
The GLP-1 drug market has expanded significantly in 2025. Novo Nordisk's CagriSema showed up to 25% weight loss in late-stage trials. Supply shortages have largely been resolved, and Medicare coverage expanded following new cardiovascular benefit data. Eli Lilly's tirzepatide continues gaining market share.
Ceramic Search
$0.05 per 1,000 queries
- • GLP-1 weight loss drugs 2025
- • CagriSema Phase 3 trial results
- • FDA wegovy label expansion
- • tirzepatide vs semaglutide efficacy
- • GLP-1 cardiovascular outcomes data
- • Medicare GLP-1 coverage policy 2025
- • ozempic supply chain status
- • oral semaglutide weight loss trials
- • Amgen MariTide Phase 3
- • GLP-1 drug pipeline 2025
- • obesity drug pricing trends
- • global weight loss drug market size
12 Searches
The GLP-1 landscape has transformed in 2025.[1] Novo Nordisk's CagriSema demonstrated 25.3% average weight loss in Phase 3, combining semaglutide with cagrilide.[2] The FDA expanded Wegovy's label to include cardiovascular risk reduction based on the SELECT trial.[3] Eli Lilly's tirzepatide achieved 22.4% weight loss in head-to-head comparisons.[4] Medicare Part D now covers GLP-1s for obesity following CMS policy changes.[5] Amgen's MariTide entered Phase 3 with a once-monthly dosing advantage.[6] The global obesity drug market is projected to reach $150B by 2030.[7]
4x
more searches
70x
cheaper
What Smarter AI Is Built On
Any industry, any application — built on AI, powered by search.
AI Agents
Agents require dozens of searches per task. Ceramic's price point makes high-frequency agentic search viable for the first time.
Verification & Fact-Checking
Verifies claims at inference time — fast and affordable enough to check every response before it reaches the user.
RAG / Context Grounding
Fills the model's context window with current web data before it responds, so answers are grounded in today's information — not training data.
AI Chatbots & Answer Engines
Users expect current answers. Search ensures your chatbot never responds based on outdated information.
Enterprise-Ready
Enterprise-Ready
Private Data Indexing
Index and search over your internal knowledge. Your data never leaves your environment.
Custom Rate Limits
Rate limits tailored to your requirements. Scale with confidence.
Dedicated Support
A dedicated team to help you integrate, scale, and succeed.
SOC 2 Type II Certified
Zero Data Retention
To include your public data, add Allow: TerraCotta to your robots.txt.